

# Hematologic Malignancies-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/H8B2E65B101MEN.html>

Date: May 2018

Pages: 153

Price: US\$ 3,480.00 (Single User License)

ID: H8B2E65B101MEN

## Abstracts

### Report Summary

Hematologic Malignancies-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Hematologic Malignancies industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Hematologic Malignancies 2013-2017, and development forecast 2018-2023

Main market players of Hematologic Malignancies in EMEA, with company and product introduction, position in the Hematologic Malignancies market

Market status and development trend of Hematologic Malignancies by types and applications

Cost and profit status of Hematologic Malignancies, and marketing status

Market growth drivers and challenges

The report segments the EMEA Hematologic Malignancies market as:

EMEA Hematologic Malignancies Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Hematologic Malignancies Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Leukemia  
Lymphoma  
Multiple Myeloma  
Others

EMEA Hematologic Malignancies Market: Application Segment Analysis (Consumption  
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Chemotherapy  
Radiotherapy  
Immunotherapy  
Stem Cell Transplantation  
Others

EMEA Hematologic Malignancies Market: Players Segment Analysis (Company and  
Product introduction, Hematologic Malignancies Sales Volume, Revenue, Price and  
Gross Margin):

Pfizer, Inc.  
F. Hoffmann-LA Roche Ltd  
Sanofi-Aventis  
Bristol-Myers Squibb Company  
AbbVie, Inc.  
Novartis AG  
GlaxoSmithKline PLC  
Celgene Corporation  
Johnson & Johnson Services, Inc.  
Takeda Pharmaceutical Company limited

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF HEMATOLOGIC MALIGNANCIES**

- 1.1 Definition of Hematologic Malignancies in This Report
- 1.2 Commercial Types of Hematologic Malignancies
  - 1.2.1 Leukemia
  - 1.2.2 Lymphoma
  - 1.2.3 Multiple Myeloma
  - 1.2.4 Others
- 1.3 Downstream Application of Hematologic Malignancies
  - 1.3.1 Chemotherapy
  - 1.3.2 Radiotherapy
  - 1.3.3 Immunotherapy
  - 1.3.4 Stem Cell Transplantation
  - 1.3.5 Others
- 1.4 Development History of Hematologic Malignancies
- 1.5 Market Status and Trend of Hematologic Malignancies 2013-2023
  - 1.5.1 Asia Pacific Hematologic Malignancies Market Status and Trend 2013-2023
  - 1.5.2 Regional Hematologic Malignancies Market Status and Trend 2013-2023

### **CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Hematologic Malignancies in Asia Pacific 2013-2017
- 2.2 Consumption Market of Hematologic Malignancies in Asia Pacific by Regions
  - 2.2.1 Consumption Volume of Hematologic Malignancies in Asia Pacific by Regions
  - 2.2.2 Revenue of Hematologic Malignancies in Asia Pacific by Regions
- 2.3 Market Analysis of Hematologic Malignancies in Asia Pacific by Regions
  - 2.3.1 Market Analysis of Hematologic Malignancies in China 2013-2017
  - 2.3.2 Market Analysis of Hematologic Malignancies in Japan 2013-2017
  - 2.3.3 Market Analysis of Hematologic Malignancies in Korea 2013-2017
  - 2.3.4 Market Analysis of Hematologic Malignancies in India 2013-2017
  - 2.3.5 Market Analysis of Hematologic Malignancies in Southeast Asia 2013-2017
  - 2.3.6 Market Analysis of Hematologic Malignancies in Australia 2013-2017
- 2.4 Market Development Forecast of Hematologic Malignancies in Asia Pacific 2018-2023
  - 2.4.1 Market Development Forecast of Hematologic Malignancies in Asia Pacific 2018-2023
  - 2.4.2 Market Development Forecast of Hematologic Malignancies by Regions

2018-2023

## **CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Whole Asia Pacific Market Status by Types

#### 3.1.1 Consumption Volume of Hematologic Malignancies in Asia Pacific by Types

#### 3.1.2 Revenue of Hematologic Malignancies in Asia Pacific by Types

### 3.2 Asia Pacific Market Status by Types in Major Countries

#### 3.2.1 Market Status by Types in China

#### 3.2.2 Market Status by Types in Japan

#### 3.2.3 Market Status by Types in Korea

#### 3.2.4 Market Status by Types in India

#### 3.2.5 Market Status by Types in Southeast Asia

#### 3.2.6 Market Status by Types in Australia

### 3.3 Market Forecast of Hematologic Malignancies in Asia Pacific by Types

## **CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

### 4.1 Demand Volume of Hematologic Malignancies in Asia Pacific by Downstream Industry

### 4.2 Demand Volume of Hematologic Malignancies by Downstream Industry in Major Countries

#### 4.2.1 Demand Volume of Hematologic Malignancies by Downstream Industry in China

#### 4.2.2 Demand Volume of Hematologic Malignancies by Downstream Industry in Japan

#### 4.2.3 Demand Volume of Hematologic Malignancies by Downstream Industry in Korea

#### 4.2.4 Demand Volume of Hematologic Malignancies by Downstream Industry in India

#### 4.2.5 Demand Volume of Hematologic Malignancies by Downstream Industry in Southeast Asia

#### 4.2.6 Demand Volume of Hematologic Malignancies by Downstream Industry in Australia

### 4.3 Market Forecast of Hematologic Malignancies in Asia Pacific by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HEMATOLOGIC MALIGNANCIES**

### 5.1 Asia Pacific Economy Situation and Trend Overview

### 5.2 Hematologic Malignancies Downstream Industry Situation and Trend Overview

## **CHAPTER 6 HEMATOLOGIC MALIGNANCIES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC**

- 6.1 Sales Volume of Hematologic Malignancies in Asia Pacific by Major Players
- 6.2 Revenue of Hematologic Malignancies in Asia Pacific by Major Players
- 6.3 Basic Information of Hematologic Malignancies by Major Players
  - 6.3.1 Headquarters Location and Established Time of Hematologic Malignancies Major Players
  - 6.3.2 Employees and Revenue Level of Hematologic Malignancies Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 HEMATOLOGIC MALIGNANCIES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Pfizer, Inc.
  - 7.1.1 Company profile
  - 7.1.2 Representative Hematologic Malignancies Product
  - 7.1.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
- 7.2 F. Hoffmann-LA Roche Ltd
  - 7.2.1 Company profile
  - 7.2.2 Representative Hematologic Malignancies Product
  - 7.2.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of F. Hoffmann-LA Roche Ltd
- 7.3 Sanofi-Aventis
  - 7.3.1 Company profile
  - 7.3.2 Representative Hematologic Malignancies Product
  - 7.3.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
- 7.4 Bristol-Myers Squibb Company
  - 7.4.1 Company profile
  - 7.4.2 Representative Hematologic Malignancies Product
  - 7.4.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company
- 7.5 AbbVie, Inc.

- 7.5.1 Company profile
- 7.5.2 Representative Hematologic Malignancies Product
- 7.5.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of AbbVie, Inc.
- 7.6 Novartis AG
  - 7.6.1 Company profile
  - 7.6.2 Representative Hematologic Malignancies Product
  - 7.6.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Novartis AG
- 7.7 GlaxoSmithKline PLC
  - 7.7.1 Company profile
  - 7.7.2 Representative Hematologic Malignancies Product
  - 7.7.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of GlaxoSmithKline PLC
- 7.8 Celgene Corporation
  - 7.8.1 Company profile
  - 7.8.2 Representative Hematologic Malignancies Product
  - 7.8.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.9 Johnson & Johnson Services, Inc.
  - 7.9.1 Company profile
  - 7.9.2 Representative Hematologic Malignancies Product
  - 7.9.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Johnson & Johnson Services, Inc.
- 7.10 Takeda Pharmaceutical Company limited
  - 7.10.1 Company profile
  - 7.10.2 Representative Hematologic Malignancies Product
  - 7.10.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company limited

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HEMATOLOGIC MALIGNANCIES**

- 8.1 Industry Chain of Hematologic Malignancies
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HEMATOLOGIC MALIGNANCIES**

- 9.1 Cost Structure Analysis of Hematologic Malignancies
- 9.2 Raw Materials Cost Analysis of Hematologic Malignancies
- 9.3 Labor Cost Analysis of Hematologic Malignancies
- 9.4 Manufacturing Expenses Analysis of Hematologic Malignancies

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF HEMATOLOGIC MALIGNANCIES**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Hematologic Malignancies-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/H8B2E65B101MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H8B2E65B101MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970